Clinical Interpretation of Platelet Activation Marker sCLEC-2 in Antiphospholipid Syndrome. Journal Abstract - Guideline Central

Clinical Interpretation of Platelet Activation Marker sCLEC-2 in Antiphospholipid Syndrome.

Published: 2026 Apr 17

Authors

, , ,

Abstract

Soluble C-type lectin-like receptor 2 (sCLEC-2) has emerged as a biomarker of platelet activation and thrombus formation. Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and pregnancy complications, driven in part by platelet activation. However, the clinical utility of sCLEC-2 and the sCLEC-2/D-dimer ratio in APS remains unclear.

Keywords: anticardiolipin antibodies, antiphospholipid syndrome, anti‐β2‐glycoprotein I antibodies, soluble form of C‐type lectin‐like receptor 2

Source

Journal of clinical laboratory analysis

Publication Type

Journal Article

Language

English

PubMed ID

41994896

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.